• Approval for Remplir™ nerve repair device to be used across the U.S. Department of Defence and Veterans Affairs hospital networks
• Access to 51 DoD military hospitals and 170 VA medical centres
• Leveraging existing U.S. distributor network to target military and VA surgeons

Orthocell Limited (ASX: OCC) has secured approval for its Remplir™ nerve repair device to be used across the United States Department of Defence (DoD) and Veterans Affairs (VA) hospital networks. This approval provides access to approximately 51 DoD military hospitals and 170 VA medical centres across the United States, representing a significant milestone in expanding Orthocell's access to the U.S. market. Orthocell's established U.S. distributor network, which currently covers 17 states, will now target military and VA surgeons operating within these hospital systems. This expansion into the defence setting follows the recent clinical use of Remplir in 23 surgical procedures on injured soldiers in Ukraine, across both primary and secondary nerve repair applications. The Ukraine experience demonstrates the real-world performance of Remplir in a conflict environment and highlights key attributes of the device, including its portability, ease of use, and suitability for treating major traumatic injuries commonly encountered in military settings. Orthocell believes this validation further supports Remplir's applicability within defence healthcare systems and reinforces its potential to address the needs of military surgeons treating complex nerve injuries.

Orthocell is well positioned to capitalise on this expanded access with its existing network of distributors and in-house sales and medical education teams, and will continue to pursue opportunities to increase utilisation of Remplir across key U.S. healthcare segments, including military and veteran care.